Ibrutinib included among the 10 drugs slated for Medicare price negotiations

Ibrutinib is included in the list of the first 10 prescription medications to be included in Medicare's price negotiations with drug manufacturers. The Centers for Medicare & Medicaid Services selected the agents using the following criteria: they account for the highest Medicare spending, they have been on the market for years, and they do not face competition from a less expensive generic competitor to drive down their prices. Negotiations are expected to be ongoing in 2023 and 2024, with any new negotiated drug pricing expected to go into effect in 2026.